Cardiac arrhythmias nursing: VT vs VFib recognition, cardioversion joules, and torsades

Cardiac arrhythmias – also called dysrhythmias – are disturbances in the rate, rhythm, origin, or conduction of the heart’s electrical impulse. They range from benign variants discovered incidentally to immediately life-threatening emergencies requiring defibrillation within minutes. For nursing students, arrhythmias are high-yield across every clinical setting: med-surg patients develop new-onset supraventricular tachycardia (SVT) postoperatively, ICU patients deteriorate into pulseless ventricular tachycardia, and outpatients with pacemakers present with failure-to-capture on a routine EKG strip. This article covers the arrhythmias most likely to appear on the NCLEX and in clinical practice – SVT, ventricular tachycardia, ventricular fibrillation, torsades de pointes, bradyarrhythmias, and heart block – along with pacemaker nursing, cardioversion and defibrillation, antiarrhythmic pharmacology, and ACLS priorities. For atrial fibrillation specifically, see the dedicated atrial fibrillation nursing reference; this article treats it as context rather than primary subject matter.

Quick reference: major arrhythmias at a glance

Classification framework

Arrhythmias are organized by origin and mechanism:

By origin:

• Supraventricular – originate above the bundle of His (SA node, atria, AV node). QRS is typically narrow because ventricular conduction follows the normal His-Purkinje pathway.
• Ventricular – originate below the bundle of His. QRS is wide and bizarre because ventricular depolarization spreads slowly through muscle rather than fast-conducting Purkinje fibers.
• Conduction system disorders – SA node dysfunction (sick sinus syndrome, sinus bradycardia) or AV nodal/infranodal block (1st, 2nd, 3rd degree).

By mechanism:

• Abnormal automaticity – a cell outside the SA node fires spontaneously (ectopic foci in VT, accelerated junctional rhythm).
• Re-entry – an impulse circles repeatedly through a closed loop of conductive tissue (SVT, AF, atrial flutter, most VTs in structural heart disease).
• Triggered activity – afterdepolarizations following a normal action potential (torsades de pointes, digoxin toxicity arrhythmias).

Robust EKG interpretation is the foundation of arrhythmia recognition. For a systematic approach to reading a rhythm strip, see the EKG interpretation cheat sheet.

Supraventricular tachycardias

SVT (paroxysmal supraventricular tachycardia)

Paroxysmal supraventricular tachycardia (PSVT) typically affects people with structurally normal hearts. Most cases result from AV nodal re-entry (AVNRT, the most common form) – a re-entry circuit confined to or near the AV node – or from an accessory pathway (AVRT, as in Wolff-Parkinson-White syndrome). The atrial rate is 150–250 bpm with narrow QRS complexes (unless aberrant conduction is present). P waves are buried in the T wave or just after the QRS (retrograde conduction), making them invisible on a standard 12-lead in many cases.

Clinical presentation: Sudden-onset palpitations, lightheadedness, chest discomfort, and dyspnea. The episode stops as abruptly as it starts – this hallmark distinguishes PSVT from sinus tachycardia.

Nursing management:

1. Establish IV access and apply continuous telemetry monitoring.
2. Coach a vagal maneuver. The modified Valsalva works best: the patient strains for 15 seconds semi-recumbent, then is laid flat with the legs raised. In the REVERT trial it restored sinus rhythm in 43% of patients vs 17% with a standard Valsalva. Carotid sinus massage is an alternative for the provider (avoid with a carotid bruit or prior stroke/TIA).
3. If vagal maneuvers fail, administer adenosine 6 mg rapid IV push (the 2015 ACC/AHA/HRS SVT guideline gives both vagal maneuvers and adenosine class I recommendations for regular SVT) followed immediately by a 20 mL saline flush through the most proximal large vein available. Adenosine has a half-life of under 10 seconds – injection must be fast.
4. If 6 mg fails, give adenosine 12 mg (the label allows one further 12 mg dose).
5. Have the crash cart available. Adenosine can cause transient AV block, flushing, chest pressure, bronchospasm, and a brief pause or asystole – warn the patient and record the rhythm strip during administration.
6. For hemodynamically unstable SVT (hypotension, acute altered mental status, shock, chest pain, acute heart failure), give immediate synchronized cardioversion (2025 AHA initial energy for narrow-complex tachycardia: 100 J) rather than medication trials.
7. For recurrent SVT in Wolff-Parkinson-White: avoid AV nodal blockers (adenosine, beta blockers, verapamil, digoxin) if the patient is in pre-excited AF – these can paradoxically accelerate accessory pathway conduction and precipitate ventricular fibrillation.

Atrial flutter

Atrial flutter is a macro-re-entry circuit typically in the right atrium. The atrial rate is 250–350 bpm, producing the characteristic sawtooth flutter waves (F waves) most visible in leads II, III, aVF, and V1. The AV node cannot conduct each atrial impulse, creating physiologic block – typically 2:1, 3:1, or 4:1. The clinical clue: a regular ventricular rate of exactly 150 bpm should raise immediate suspicion for atrial flutter with 2:1 block, even when sawtooth waves are not immediately obvious.

Management priorities mirror AF: rate control (diltiazem, beta blockers), anticoagulation following the same rules as AF (the 2023 US AF guideline uses ≥48 hours or unknown duration as the trigger for 3 weeks of anticoagulation or imaging before cardioversion, and 4 weeks after), and cardioversion or ablation for rhythm control. Atrial flutter converts readily with electrical cardioversion (2025 AHA initial energy 200 J), and catheter ablation of the cavotricuspid isthmus is a first-line option for typical flutter. For the shared anticoagulation logic and cardioversion principles, see the atrial fibrillation nursing article.

Ventricular arrhythmias

Ventricular tachycardia

Ventricular tachycardia (VT) is a series of three or more consecutive ventricular beats at a rate of 100 bpm or faster, arising from a ventricular ectopic focus or re-entry circuit below the bundle of His. QRS complexes are wide (≥0.12 s) and bizarre.

Classification dimensions:

Monomorphic VT most commonly results from re-entry around a prior myocardial infarction scar. AV dissociation – P waves marching independently from the QRS – is diagnostic when present. Capture beats (a normally conducted P wave briefly depolarizes the ventricle, producing a narrow QRS amid the wide complexes) and fusion beats (partial ventricular capture producing a hybrid QRS morphology) are also diagnostic features.

Monomorphic VT with a pulse:

• Assess hemodynamic stability first. If unstable (hypotension, acute altered mental status, shock, chest pain, acute heart failure): prepare for immediate synchronized cardioversion – the 2025 AHA initial energy for monomorphic VT is 100 J.
• If stable: obtain a 12-lead EKG and expect an IV antiarrhythmic. The 2025 AHA guidelines say IV procainamide or amiodarone may be considered, with synchronized cardioversion if drugs fail or are contraindicated. The amiodarone label regimen is 150 mg IV over 10 minutes, then 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours.
• Correct electrolyte imbalances (hypokalemia and hypomagnesemia are common precipitants).

Pulseless VT:

• Treat identically to ventricular fibrillation: immediate unsynchronized defibrillation, CPR, epinephrine, and amiodarone per ACLS protocol. There is no time to deliver synchronized shocks when no pulse is present.

Ventricular fibrillation

Ventricular fibrillation (VFib) is the most immediately lethal cardiac arrhythmia. There are no organized QRS complexes – only chaotic, irregular electrical activity with no effective mechanical contraction and no cardiac output. The patient is unconscious and pulseless within seconds.

EKG appearance: Coarse VFib shows large, irregular undulations. Fine VFib shows small-amplitude oscillations that can be mistaken for asystole – if uncertain on a single lead, verify on a second lead before withholding defibrillation.

Immediate management:

1. Call for help and confirm pulselessness – begin CPR immediately.
2. Apply defibrillator pads. Shock immediately – unsynchronized defibrillation at the manufacturer’s recommended biphasic energy (typically 120–200 J; use the maximum if unknown).
3. Resume CPR for 2 minutes after each shock before rhythm check.
4. Establish vascular access during CPR – the 2025 AHA guidelines recommend trying IV access first, with IO if IV attempts fail.
5. Epinephrine 1 mg IV/IO every 3–5 minutes, starting after initial shocks have failed (the algorithm places it after the second shock).
6. For VFib that persists after shocks (after the third shock in the algorithm), give amiodarone 300 mg IV/IO bolus (second dose 150 mg).
7. Lidocaine is an equal alternative to amiodarone: 1–1.5 mg/kg IV/IO first dose, then 0.5–0.75 mg/kg.
8. Identify and treat reversible causes (the H’s and T’s – hypovolemia, hypoxia, hydrogen ion acidosis, hypo/hyperkalemia, hypothermia; tension pneumothorax, tamponade, toxins, thrombosis pulmonary/coronary).

Survival from VFib falls with every minute of delay. In Larsen’s King County model of out-of-hospital VF arrest (1,667 patients), survival dropped about 5.5% per minute when no CPR, defibrillation, or advanced care was given, and each minute’s delay to defibrillation cost survival even when CPR was under way. After ROSC, the AHA recommends a MAP of at least 65 mm Hg, SpO₂ 90–98%, and deliberate temperature control for patients who do not follow commands: one target temperature between 32°C and 37.5°C held for at least 24 hours, and at least 36 hours is reasonable if the patient stays unresponsive. These patients often require mechanical ventilation in the ICU setting.

Torsades de pointes

Torsades de pointes (TdP) is a form of polymorphic VT occurring in the setting of prolonged QT interval. The QRS complexes appear to rotate or “twist” around the isoelectric baseline – the hallmark feature giving the arrhythmia its French name (“twisting of the points”). TdP is triggered by early afterdepolarizations, a form of triggered automaticity promoted when the QT interval is lengthened.

Causes of QT prolongation (acquired):

• Medications: antiarrhythmics (sotalol, quinidine, procainamide), antibiotics (azithromycin, fluoroquinolones), antipsychotics (haloperidol, quetiapine), methadone
• Electrolyte disorders: hypokalemia, hypomagnesemia, hypocalcemia
• Hypothyroidism, bradycardia, intracranial events
• Congenital long QT syndrome (Romano-Ward, Jervell-Lange-Nielsen)

QTc thresholds: The AHA/ACCF hospital statement (Drew 2010) treats a QTc above the 99th percentile as prolonged – about 470 ms in men and 480 ms in women – and a QTc >500 ms as highly abnormal, with a 2- to 3-fold higher TdP risk. A rise of more than 60 ms from the patient’s baseline is also a warning sign. Some EKG machines flag >440 ms as “borderline,” which is not the same as dangerous prolongation. Nurses must recognize prolonged QTc on telemetry before the arrhythmia occurs.

Treatment of torsades de pointes:

1. If TdP is sustained, causes instability, or degenerates to VFib: give an immediate unsynchronized shock at the defibrillation dose (2025 AHA). Synchronized mode cannot track the changing QRS.
2. Magnesium sulfate 2 g IV – first-line drug therapy regardless of the serum magnesium level, with a repeat 2 g dose if episodes persist (Drew 2010). How magnesium suppresses TdP is not known. The 2025 AHA guidelines say magnesium may be considered for TdP; it does not help polymorphic VT with a normal QT.
3. Discontinue all QT-prolonging medications immediately.
4. Correct electrolytes: replete potassium (Drew 2010 notes that some clinicians target 4.5–5 mmol/L, a class IIb measure with little evidence) and keep magnesium normal.
5. Temporary pacing (transvenous atrial or ventricular) at rates above 70/min prevents the pauses that trigger TdP – used for bradycardia- or pause-dependent TdP or episodes that keep recurring.
6. Isoproterenol infusion (raises heart rate, shortens QT) may be used as a bridge to pacing in acquired TdP.

Bradyarrhythmias

Sinus bradycardia

Sinus bradycardia is a sinus rhythm at a rate below 60 bpm. It is normal in well-conditioned athletes and during sleep. Pathological causes include inferior myocardial infarction (right coronary artery supplies the SA node in 60% of people), hypothyroidism, increased vagal tone, and medications (beta blockers, calcium channel blockers, digoxin, amiodarone).

When treatment is needed: Bradycardia causing symptoms – hypotension, syncope, altered consciousness, chest pain, or acute heart failure. Asymptomatic sinus bradycardia in an athlete requires no treatment.

Management:

• Atropine 1 mg IV – blocks vagal inhibition of the SA node. May repeat every 3–5 minutes to a maximum dose of 3 mg. (The AHA raised the dose from 0.5 mg to 1 mg in 2020.)
• If atropine fails: transcutaneous pacing while preparing transvenous access.
• Dopamine 5–20 mcg/kg/min or epinephrine 2–10 mcg/min infusion as a bridge.
• Treat reversible causes: reverse offending medications, correct hypothyroidism, replete electrolytes.

Heart blocks

Heart blocks are disorders of AV conduction. A thorough review of first-degree, second-degree (Mobitz I and Mobitz II), and third-degree heart block is available in the heart block poem article, which also covers clinical mnemonics for distinguishing Wenckebach from Mobitz II.

Key points for NCLEX:

• First-degree AV block: PR >0.20 s. Every P wave conducts. Usually no treatment required – monitor and identify cause.
• Mobitz I (Wenckebach): Progressive PR lengthening until a QRS is dropped, then the cycle resets. Generally benign – most commonly inferior MI, AV node medication effect, or increased vagal tone. Atropine if symptomatic.
• Mobitz II: Constant PR interval with intermittent, unpredictable dropped QRS complexes. The block is usually infranodal (His bundle or bundle branches), so atropine is often ineffective. Mobitz II can deteriorate abruptly to complete heart block. The 2018 ACC/AHA/HRS bradycardia guideline recommends a permanent pacemaker when no reversible cause is found; temporary pacing bridges an unstable patient.
• Third-degree (complete) heart block: No relationship between P waves and QRS. The ventricles beat at an escape rate (20–40 bpm ventricular escape; 40–60 bpm junctional escape). If the patient is symptomatic or hypotensive, start transcutaneous pacing immediately and prepare for transvenous pacing. A permanent pacemaker is recommended unless the cause is reversible (for example, drug toxicity or hyperkalemia).

Sepsis and hypertensive emergencies are two systemic conditions that can precipitate or unmask conduction disorders through ischemia, metabolic derangement, or direct myocardial injury.

Cardioversion vs defibrillation

These two procedures both deliver electrical energy to the heart but differ in timing, indication, and energy delivery.

Critical NCLEX distinction: A patient in VFib needs unsynchronized defibrillation. If a nurse selects “synchronized” mode for VFib, the defibrillator cannot identify an R wave and the shock will not be delivered – resulting in a fatal delay. Always verify the mode before charging.

Elective cardioversion nursing checklist:

• Confirm NPO status (typically ≥6 hours solids, ≥2 hours clear liquids)
• Verify IV access and patent line
• Confirm consent obtained
• Confirm anticoagulation compliance (AF/flutter)
• Remove supplemental oxygen during shock delivery (fire hazard)
• Have airway equipment and resuscitation medications at bedside
• Administer sedation per order; monitor SpO2 and respiratory rate
• Document pre- and post-cardioversion rhythm strip, vital signs, energy levels used

Pacemaker nursing

Types and terminology

Pacemakers deliver an electrical stimulus to the myocardium when the heart’s intrinsic rate falls below the programmed threshold.

Temporary pacemakers:

• Transcutaneous pacing (TCP) – external pads applied to the anterior and posterior chest wall. Used in emergencies (symptomatic bradycardia, complete heart block). Rate and output (mA) are dialed in on the defibrillator/pacer unit. TCP is painful – IV analgesia and sedation are essential for conscious patients.
• Transvenous pacing – a pacing lead is threaded via central venous access (usually right internal jugular or subclavian) to the right ventricle. More reliable than TCP and better tolerated; used as a bridge to permanent pacemaker.

Permanent pacemakers:

• Subcutaneously implanted pulse generator (pocket in the chest wall) connected to leads in the right atrium, right ventricle, or both. The five-letter NASPE/BPEG code describes pacemaker programming (e.g., “DDD” = dual-chamber sensing and pacing with tracking).
• Cardiac resynchronization therapy (CRT/biventricular pacing): simultaneous left and right ventricular pacing to coordinate contraction in heart failure with left bundle branch block.
• Implantable cardioverter-defibrillator (ICD): combines pacemaker function with the ability to detect and shock VT/VFib. Indicated after cardiac arrest or sustained VT not due to a reversible cause (secondary prevention), and for primary prevention when EF is ≤35% with NYHA class II–III symptoms despite guideline-directed medical therapy (at least 40 days after MI and 90 days after revascularization), per the 2017 AHA/ACC/HRS ventricular arrhythmia guideline.

Pacemaker malfunctions

Magnet response

Placing a ring magnet over a pacemaker converts it to asynchronous mode (paces at a fixed rate regardless of intrinsic rhythm). This is used during surgical/procedural electromagnetic interference to prevent oversensing-induced inhibition. Conversely, placing a magnet over an ICD temporarily disables tachyarrhythmia detection without affecting pacing – useful when an ICD is delivering inappropriate shocks.

Post-implant nursing care and patient education

Immediate post-implant:

• Arm sling on the ipsilateral arm for 24 hours; limit arm elevation above the shoulder for 4–6 weeks (prevents lead dislodgement).
• Incision care: keep dry for 48–72 hours; monitor for hematoma, erythema, or pocket swelling.
• Telemetry monitoring for 24 hours post-implant – detect early lead displacement (failure to capture/pace).
• Post-procedure chest X-ray to confirm lead position and exclude pneumothorax.

Ongoing patient education:

• Carry pacemaker ID card at all times; alert healthcare providers before any procedure.
• MRI: modern MRI-conditional pacemakers allow imaging with specific protocols – the patient should know the pacemaker model. Never assume MRI is safe without confirming MRI-conditional status.
• Cell phones: hold on the contralateral side; avoid placing phone directly over the device.
• Airport security/metal detectors: will set off detectors; use pacemaker card; the brief detector exposure is not harmful.
• Household appliances (microwave ovens, electric shavers, small power tools): generally safe with modern pacemakers – current guidance from major manufacturers does not restrict routine use of properly functioning household appliances.
• High-powered electromagnetic sources to avoid: arc welding equipment, large industrial generators, MRI scanners without conditional clearance, diathermy/electrocautery (surgical team must use bipolar mode; program pacemaker to asynchronous before major procedures).
• ICD patients: counsel on driving restrictions (AHA/HRS: no private driving for at least 1 week after a primary-prevention ICD; longer restrictions, commonly 6 months, after a secondary-prevention ICD or an appropriate shock for VT/VF; state rules vary), and what to do if a shock fires (sit down, call provider; call 911 if a second shock fires within minutes or if symptoms persist).

Antiarrhythmic medications

See the drug classifications nursing article for a broader overview of antiarrhythmic drug class pharmacology in the context of nursing pharmacology coursework.

ACLS context: shockable vs non-shockable rhythms

The most critical ACLS decision during cardiac arrest is determining whether the rhythm is shockable or non-shockable – because the interventions differ completely.

PEA (pulseless electrical activity): Organized EKG activity (sinus rhythm, bradycardia, IVCD) with no palpable pulse. The rhythm appears perfusing – the absence of a pulse is the critical finding. PEA usually has an underlying cause that can be treated if it is found quickly. Systematic search for H’s and T’s (hypovolemia, hypoxia, hydrogen ion/acidosis, hypo/hyperkalemia, hypothermia; tamponade, tension pneumothorax, toxins, thrombosis) drives treatment.

Asystole: Flat line with no electrical or mechanical activity. Confirm in at least two leads and check gain and lead connections (fine VFib can mimic asystole). CPR and epinephrine are the only interventions – atropine is no longer included in current ACLS guidelines for asystole/PEA.

NANDA-I nursing care plans

Cardiac arrhythmias generate a predictable cluster of nursing diagnoses regardless of the specific rhythm. The five diagnoses below cover the core clinical problems: impaired pump function, perfusion failure, arrhythmia progression risk, psychological distress on telemetry or after ICD shocks, and knowledge gaps that compromise long-term self-management.

1. Decreased cardiac output

Nursing diagnosis: Decreased cardiac output related to altered electrical conduction as evidenced by arrhythmia on telemetry, abnormal heart rate or rhythm, and hemodynamic instability.

Goal: Patient will maintain adequate cardiac output as evidenced by systolic blood pressure ≥90 mmHg, oriented mentation, urine output ≥0.5 mL/kg/hr, and absence of symptomatic arrhythmia by end of shift.

2. Risk for decreased cardiac output

Nursing diagnosis: Risk for decreased cardiac output related to potential for arrhythmia progression as evidenced by underlying structural heart disease, post-MI status, prolonged QTc, or known conduction system disease.

Goal: Patient will remain free of hemodynamic deterioration as evidenced by stable vital signs, absence of new arrhythmia, and QTc maintained below 500 ms throughout hospitalization.

3. Risk for decreased cardiac tissue perfusion

Older care-plan books use “ineffective tissue perfusion (cardiopulmonary).” NANDA-I 2021–2023 no longer lists that label; its perfusion diagnoses include risk for decreased cardiac tissue perfusion, risk for ineffective cerebral tissue perfusion, and ineffective peripheral tissue perfusion.

Nursing diagnosis: Risk for decreased cardiac tissue perfusion related to reduced cardiac output and a myocardial oxygen supply–demand mismatch during sustained or rapid arrhythmia. Watch for altered mentation, diaphoresis, cool extremities, falling oxygen saturation, chest pain, or dyspnea, which signal that systemic and coronary perfusion is failing.

Goal: Patient will demonstrate improved tissue perfusion as evidenced by return to baseline mental status, warm and dry skin, SpO₂ ≥94%, and resolution of chest pain or dyspnea within 1 hour of intervention.

4. Anxiety

Nursing diagnosis: Anxiety related to perceived threat to health status, uncertainty about arrhythmia recurrence, and fear of ICD shocks as evidenced by verbalized fear, restlessness, tachycardia in excess of the underlying arrhythmia, and requesting repeated reassurance.

Goal: Patient will report anxiety reduced to 3/10 or less on a numeric rating scale and demonstrate at least one effective coping strategy before discharge.

5. Deficient knowledge

Nursing diagnosis: Deficient knowledge related to unfamiliarity with arrhythmia diagnosis, antiarrhythmic medications, and pacemaker or ICD self-management as evidenced by questions about device function, inability to state when to call 911, and verbalized uncertainty about activity restrictions.

Goal: Patient will verbalize understanding of their arrhythmia type, medication regimen, device function, warning signs requiring emergency care, and at least three activity restrictions before discharge.

Frequently asked questions

What is the priority nursing assessment for a patient with a new cardiac arrhythmia?

The priority assessment is hemodynamic status – specifically whether the patient has a pulse, adequate blood pressure (SBP ≥90 mmHg), and intact mental status. An arrhythmia in a patient who is alert, oriented, and hemodynamically stable is managed differently from the same rhythm in a patient who is hypotensive or unconscious. After confirming hemodynamic status, assess the rhythm via telemetry or 12-lead EKG, and simultaneously gather a focused history – symptom onset, prior arrhythmia episodes, and current medications including QT-prolonging agents.

What is the difference between synchronized cardioversion and defibrillation?

Synchronized cardioversion delivers an electrical shock timed to the R wave of the cardiac cycle, avoiding the T wave refractory period – because a shock on the T wave can induce ventricular fibrillation (R-on-T phenomenon). It is used for rhythms with an identifiable QRS complex and a pulse: hemodynamically unstable SVT, atrial flutter, AF with rapid ventricular response, and VT with a pulse. Defibrillation is unsynchronized and delivered immediately on command, without regard for the cardiac cycle. It is used for pulseless VT, ventricular fibrillation, and unstable polymorphic VT (including torsades), where there is no consistent QRS to synchronize to and no time to delay the shock. A critical NCLEX point: selecting synchronized mode during VFib prevents the machine from firing because it cannot find an R wave – the result is a fatal delay.

What are the most common nursing diagnoses for cardiac arrhythmias?

The five NANDA-I diagnoses most consistently applied to cardiac arrhythmia patients are: (1) decreased cardiac output related to altered electrical conduction; (2) risk for decreased cardiac output related to arrhythmia progression or high-risk substrate; (3) risk for decreased cardiac tissue perfusion related to reduced cardiac output (older texts call this ineffective tissue perfusion, cardiopulmonary); (4) anxiety related to perceived threat to health and fear of ICD shocks; and (5) deficient knowledge related to arrhythmia self-management, medications, and device safety. In patients with atrial fibrillation or post-cardioversion, risk for injury related to anticoagulation therapy is also frequently applicable.

When should a nurse call a rapid response for a patient with an arrhythmia?

Call a rapid response immediately for any of the following: new onset of VT or VFib, regardless of hemodynamic status; loss of consciousness or near-syncope with an arrhythmia; SBP <90 mmHg with concurrent arrhythmia; HR <40 bpm or >150 bpm with hemodynamic compromise; complete heart block or new wide-complex tachycardia in a patient not previously known to have these rhythms; or pulselessness – which requires immediate activation of a full cardiac arrest team rather than rapid response. Any patient who “looks bad” on clinical intuition despite normal monitors warrants escalation: arrhythmia patients can decompensate rapidly.

What are the nursing considerations for amiodarone administration?

Amiodarone infusions lasting longer than 2 hours must run from glass or polyolefin containers, and concentrations above 2 mg/mL for more than 1 hour need a central line. The drug leaches DEHP plasticizer from PVC; the label doses already account for PVC tubing. The loading dose for stable VT is 150 mg IV over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours. Monitor for hypotension during the infusion, which is the most common IV adverse effect. Amiodarone prolongs QTc – monitor at baseline and with each dose change. Long-term oral use requires regular monitoring of thyroid function (TSH/free T4), liver enzymes (AST/ALT), the lungs (chest X-ray, PFTs), and the eyes. Counsel patients on photosensitivity (about 10% of patients) – sunscreen (SPF 30+) and protective clothing year-round – because the drug persists in tissues for weeks to months after it is stopped (label half-life 15–142 days).

How does a nurse distinguish ventricular tachycardia from supraventricular tachycardia with aberrant conduction?

Both VT and SVT with aberrancy produce wide-complex tachycardia, making distinction challenging. Several EKG findings strongly favor VT: AV dissociation (P waves marching independently of QRS at a slower rate) – this is diagnostic of VT when present; capture beats (a narrow QRS amid wide complexes indicating a normal sinus impulse briefly conducted); fusion beats (a hybrid QRS from simultaneous ventricular and sinus activation); and QRS width ≥0.16 s. A concordantly positive or negative QRS across all precordial leads (V1–V6) also favors VT. In clinical practice, treat any wide-complex tachycardia as VT until proven otherwise, because misidentifying VT as SVT and giving verapamil or adenosine can cause hemodynamic collapse in a patient with structural heart disease and VT.

What is the nursing management of a patient with a pacemaker who shows failure to capture?

Failure to capture is identified by pacemaker spikes on telemetry that are not followed by a P wave or QRS complex – the myocardium is not responding to the electrical stimulus. Immediate nursing actions include increasing the output (mA) per protocol or on provider order, repositioning the patient to left lateral decubitus (which may improve endocardial contact in transvenous systems), checking all external connections if using a temporary transvenous pacer, and notifying the cardiologist urgently. Check serum potassium and pH, as hyperkalemia and acidosis raise the pacing threshold and cause capture failure independently of lead issues. Prepare for lead repositioning or revision in the case of permanent pacemaker lead displacement. Document the telemetry strip before and after any intervention.

What is the first-line treatment for torsades de pointes and what does the nurse monitor for?

If TdP is sustained, causes instability, or degenerates to VFib, the first step is an immediate unsynchronized (defibrillation-dose) shock. The first-line drug is magnesium sulfate 2 g IV, regardless of the serum magnesium level, repeated if episodes persist (AHA/ACCF, Drew 2010); how magnesium suppresses TdP is not known. Simultaneously, discontinue all QT-prolonging medications, replete potassium (some clinicians target 4.5–5 mmol/L, a class IIb measure with little evidence), and correct hypomagnesemia. If TdP keeps recurring or is pause- or bradycardia-dependent, temporary transvenous pacing at rates above 70/min prevents the pauses that trigger it. For magnesium toxicity monitoring: assess deep tendon reflexes (loss of the patellar reflex is the earliest sign), monitor respiratory rate (hold infusion if <12 breaths/min), check urine output (hold if <25 mL/hr), and keep calcium gluconate 1 g IV at the bedside as the antidote.

NCLEX tips

1. Ventricular rate of exactly 150 bpm in a regular tachycardia should immediately raise suspicion for atrial flutter with 2:1 block – not sinus tachycardia.

2. Adenosine must be given as a rapid IV push (followed immediately by a fast saline flush) through the largest, most proximal vein available. A slow push fails – the drug is inactivated before reaching the heart.

3. VFib and pulseless VT are the only cardiac arrest rhythms that respond to defibrillation. PEA and asystole require CPR and epinephrine – shocking them does nothing.

4. Torsades de pointes = first-line magnesium sulfate, regardless of the serum magnesium level. Also stop all QT-prolonging drugs. If the patient is unstable or pulseless, defibrillate (unsynchronized) first.

5. Amiodarone toxicity targets: lungs (pulmonary fibrosis), liver (hepatotoxicity), thyroid (hypo- or hyperthyroidism), eyes (corneal microdeposits, optic neuropathy), skin (photosensitivity, blue-gray discoloration). Monitor all five systems.

6. Digoxin toxicity is precipitated by hypokalemia. Classic signs: bradycardia, heart block, yellow-green vision (xanthopsia), nausea and vomiting. Low potassium increases myocardial sensitivity to digoxin even at therapeutic serum levels.

7. Atropine is ineffective for Mobitz II and complete heart block – the block is infranodal (below the AV node), outside the reach of vagal blockade. Pacing is required.

8. Failure to capture vs failure to pace: Failure to capture = spikes present, no response. Failure to pace = no spikes when expected. These require different interventions (increase mA for capture; check connections/sensitivity for failure to pace).

9. Synchronized cardioversion requires a detectable R wave. Never select synchronized mode for VFib – there is no R wave, the machine cannot fire, and the patient deteriorates while the nurse waits for a shock that never comes.

10. Adenosine is contraindicated in WPW with pre-excited AF. Blocking the AV node in WPW forces conduction down the accessory pathway at maximum speed, which can precipitate VFib.

11. A paced rhythm on a 12-lead shows wide QRS complexes with LBBB morphology – this is expected because ventricular pacing from the right ventricular apex depolarizes the left ventricle late. Do not confuse this with pathological VT; look for the pacemaker spike before the QRS.

12. Magnesium sulfate nursing antidote: calcium gluconate 1 g IV reverses magnesium toxicity. Always have it at the bedside. Signs of toxicity: loss of deep tendon reflexes (earliest sign), respiratory depression, hypotension, cardiac arrest.

13. Post-cardioversion nursing: Assess airway, breathing, and circulation first after sedation/cardioversion. Document the post-procedure rhythm. Maintain NPO until fully alert. Monitor for skin burns at pad sites.

14. R-on-T phenomenon: A premature ventricular contraction that falls on the T wave of the preceding beat (the vulnerable period) can trigger VFib. This is why synchronized cardioversion avoids the T wave and why undersensing (pacemaker firing randomly in the cycle) carries clinical risk.

15. Epinephrine is used in both shockable and non-shockable ACLS algorithms, but timing differs: in VFib/pulseless VT, give it once initial shocks have failed (after the 2nd shock in the AHA algorithm); in PEA/asystole, give it as soon as feasible.

16. The QTc – not the raw QT – is the relevant interval. QT naturally shortens with faster heart rates; QTc corrects for rate. Bazett’s formula: QTc = QT ÷ √(R-R interval in seconds). AHA/ACCF treat a QTc above about 470 ms (men) or 480 ms (women) as prolonged; QTc >500 ms, or a rise of more than 60 ms from baseline, is high-risk for torsades.

Practice NCLEX questions

Question 1

A nurse is caring for a patient with a new permanent pacemaker implanted three hours ago for complete heart block. The patient’s telemetry now shows pacemaker spikes occurring regularly but without subsequent QRS complexes. Which action is the priority?

A. Administer atropine 1 mg IV per standing order
B. Increase the pacemaker output (mA) per protocol and notify the cardiologist
C. Place the patient in Trendelenburg position
D. Reassure the patient that this pattern is expected post-implant

Answer: B

Rationale: The rhythm description – pacemaker spikes without QRS response – is failure to capture. The most common cause in the immediate post-implant period is inadequate output relative to the pacing threshold, or early lead displacement. The intervention is to increase the output (mA). Atropine (option A) would address the intrinsic rate but does nothing for the pacemaker’s inability to stimulate the myocardium. Trendelenburg position (option C) is irrelevant. Failure to capture is never expected or normal in the post-implant period (option D).

Question 2

A nurse is preparing to administer adenosine to a patient in PSVT. Which action is most important before giving the medication?

A. Obtain a 12-lead EKG immediately after injection
B. Start a peripheral IV in the antecubital fossa and confirm patency
C. Administer with a slow push over 3–5 minutes to avoid hypotension
D. Pre-medicate with diphenhydramine to prevent flushing

Answer: B

Rationale: Adenosine must be given via rapid IV push through a large, proximal vein (antecubital or larger). Its half-life is under 10 seconds; a distal IV site allows the drug to be inactivated before reaching the AV node. A slow push (option C) is incorrect – adenosine given slowly is ineffective. A 12-lead EKG after injection (option A) is useful for documentation but is secondary. Diphenhydramine (option D) has no role in adenosine administration.

Question 3

A patient on telemetry develops a wide-complex tachycardia at 190 bpm. The QRS complexes vary in amplitude and appear to twist around the isoelectric baseline. The patient’s QTc was 530 ms on the morning EKG. Which medication does the nurse anticipate administering first?

A. Adenosine 6 mg rapid IV push
B. Amiodarone 150 mg IV over 10 minutes
C. Magnesium sulfate 2 g IV
D. Lidocaine 1.5 mg/kg IV bolus

Answer: C

Rationale: The description – wide-complex tachycardia with QRS amplitude twisting around the baseline in the context of prolonged QTc (530 ms) – is torsades de pointes. First-line pharmacologic treatment is magnesium sulfate 2 g IV regardless of serum magnesium level. Adenosine (option A) terminates re-entrant SVTs that use the AV node (AVNRT, AVRT) and should be avoided in irregular or polymorphic wide-complex tachycardia. Amiodarone (option B) prolongs the QT interval further, potentially worsening torsades. Lidocaine (option D) is used for VFib and monomorphic VT, not torsades.

References

1. Wigginton JG, Agarwal S, Bartos JA, et al. Part 9: Adult advanced life support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 Suppl 2):S538–S577. doi:10.1161/CIR.0000000000001376
2. Hirsch KG, Amorim E, Coppler PJ, et al. Part 11: Post-cardiac arrest care: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 Suppl 2):S673–S718. doi:10.1161/CIR.0000000000001375
3. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol. 2018;72(14):e91–e220. doi:10.1016/j.jacc.2017.10.054
4. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. Circulation. 2019;140(8):e382–e482. doi:10.1161/CIR.0000000000000628
5. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1–e156. doi:10.1161/CIR.0000000000001193
6. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Circulation. 2016;133(14):e506–e574. doi:10.1161/CIR.0000000000000311
7. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047–1060. doi:10.1161/CIRCULATIONAHA.109.192704
8. Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015;386(10005):1747–1753. doi:10.1016/S0140-6736(15)61485-4
9. Larsen MP, Eisenberg MS, Cummins RO, Hallstrom AP. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med. 1993;22(11):1652–1658. doi:10.1016/S0196-0644(05)81302-2
10. Epstein AE, Baessler CA, Curtis AB, et al. Addendum to “Personal and public safety issues related to arrhythmias that may affect consciousness”: public safety issues in patients with implantable defibrillators. A scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation. 2007;115(9):1170–1176. doi:10.1161/CIRCULATIONAHA.106.180203
11. Magyar-Russell G, Thombs BD, Cai JX, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res. 2011;71(4):223–231. doi:10.1016/j.jpsychores.2011.02.014
12. Amiodarone hydrochloride injection [prescribing information]. DailyMed, US National Library of Medicine (setid 0a28ae25-7cc4-4ac0-a2ba-7820fb93e25c). Accessed October 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a28ae25-7cc4-4ac0-a2ba-7820fb93e25c
13. Pacerone (amiodarone hydrochloride) tablets [prescribing information]. Upsher-Smith Laboratories. DailyMed (setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7). Accessed October 12, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7
14. Wood AJ, Hohnloser SH, Woosley RL. Sotalol. N Engl J Med. 1994;331(1):31–38. doi:10.1056/NEJM199407073310108
15. Herdman TH, Kamitsuru S, Lopes CT, eds. NANDA International Nursing Diagnoses: Definitions and Classification 2021–2023. 12th ed. Thieme; 2021.